← Russell 3000 cross-section

PVLA PALVELLA THERAPEUTICS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$2.2bn
Revenue TTM
$4m
Net income TTM
$-62m
Free cash flow
Composite score
Sector rank
#1582

Valuation

P / E
EV / EBITDA
EV / sales
466.4
FCF yield
Earnings yield vs 10-yr
-7.53pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-1,473.9%
EBITDA margin
ROE
-28.4%
ROIC
Revenue growth
100.9%

Insider activity, last 90 days

Net open-market
$-1.77m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The specific pathophysiology of microcystic LMs is primarily the result of somatic activating mutations in PIK3CA that result in increased activation of the PI3K/mTOR pathway and subsequent lymphatic hyperplasia. In addition, we agreed to pay to Ligand tiered royalties ranging from 8.0% to 9.8% of any aggregate annual worldwide net product sales of any products based on QTORIN rapamycin. Product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages, primarily due to the increased size and duration of later-stage clinical trials. …PALVELLA THERAPEUTICS, INC., 10-K, period ended 2025-12-31, filed 2026-03-31

Read the full passage →